Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aligos Therapeutics, Inc.ALGS · Entity 7352 | Director | June 25, 2026 | June 29, 2026 |
| IO Biotech, Inc.IOBT · Entity 8764 | Director | June 05, 2025 | June 06, 2025 |
| TRex Bio, Inc.TRXB · Entity 184308 | Director | October 08, 2026 | October 09, 2026 |
| Vaxcyte, Inc.PCVX · Entity 1164 | Director | June 06, 2024 | June 10, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aligos Therapeutics, Inc.
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2036-06-25 | Direct | 5,860 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 5,860 · Balance 5,860 F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date.
IO Biotech, Inc.
Report date June 05, 2025 · Filed June 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2035-06-05 | Direct | 35,144 |
Reported balance
After 2025-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-05 · Grant · Acquired 35,144 · Balance 35,144 F1: These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. |
Filing footnotes · ownership attribution and instrument terms
F1: These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control.
TRex Bio, Inc.
Report date October 08, 2026 · Filed October 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2036-10-08 | Direct | 17,500 |
Reported balance
After 2026-10-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-08 · Grant · Acquired 17,500 · Balance 17,500 F1: The option vests in full on October 8, 2027, subject to the reporting person's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on October 8, 2027, subject to the reporting person's continued service through such date.
Vaxcyte, Inc.
Report date June 06, 2024 · Filed June 10, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,175 |
Reported balance
After 2024-06-06 transaction · row 1
1 source rowRow 1 · 2024-06-06 · Grant · Acquired 1,550 · Balance 7,175 F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 6, 2025 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.51 · Expires 2034-06-05 | Direct | 7,250 |
Reported balance
After 2024-06-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-06 · Grant · Acquired 7,250 · Balance 7,250 F2: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 6, 2025 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. |
| Common StockSEC Table I · non-derivative | IndirectBy Hirth Enterprises LLC | 7,113 |
Reported balance
Holding disclosure · report date 2024-06-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 7,113 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 6, 2025 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
F2: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 6, 2025 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 08, 2026 Filed Oct 9, 2026 01:50 UTC | TRex Bio, Inc. TRXB · Entity 184308 | GrantStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001193125-26-418293 · ownership.xml · derivative · entry 1 Hirth Peter · CIK 0001813780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2036-10-08 F1 · derivative.exercise_date: The option vests in full on October 8, 2027, subject to the reporting person's continued service through such date. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:35 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 5,860 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001610717-26-000300 · form4.xml · derivative · entry 1 Hirth Peter · CIK 0001813780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,860 Underlying: Common Stock · 5,860 shares Expires 2036-06-25 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. Read SEC document |
| June 25, 2025 Filed Jun 26, 2025 20:30 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 5,860 | $0.00 Strike: $7.63 | $0.00 |
DisclosureSEC source: 0001610717-25-000257 · form4.xml · derivative · entry 1 Hirth Peter · CIK 0001813780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,860 Underlying: Common Stock · 5,860 shares Expires 2035-06-25 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2026 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 20:26 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 35,144 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0000905148-25-002032 · form4.xml · derivative · entry 1 Hirth Peter · CIK 0001813780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,144 Underlying: Common Stock · 35,144 shares Expires 2035-06-05 F1 · derivative.exercise_date: These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. Read SEC document |
| June 27, 2024 Filed Jun 28, 2024 20:08 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001610717-24-000372 · form4.xml · derivative · entry 1 Hirth Peter · CIK 0001813780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-06-27 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2025 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:17 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 45,642 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0000905148-24-001685 · form4.xml · derivative · entry 1 Hirth Peter · CIK 0001813780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,642 Underlying: Common Stock · 45,642 shares Expires 2034-06-06 F1 · derivative.exercise_date: These options vest on June 6, 2025, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 7,250 | $0.00 Strike: $72.51 | $0.00 |
DisclosureSEC source: 0001649094-24-000010 · wk-form4_1718050014.xml · derivative · entry 3 Hirth Peter · CIK 0001813780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,250 Underlying: Common Stock · 7,250 shares Expires 2034-06-05 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 6, 2025 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 1,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001649094-24-000010 · wk-form4_1718050014.xml · nonDerivative · entry 1 Hirth Peter · CIK 0001813780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,175 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 6, 2025 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 22:35 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 4,411 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001610717-24-000102 · form4.xml · derivative · entry 2 Hirth Peter · CIK 0001813780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,411 Underlying: Common Stock · 4,411 shares Expires 2031-06-17 F1 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share. F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 22:35 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $26.58 | $0.00 |
DisclosureSEC source: 0001610717-24-000102 · form4.xml · derivative · entry 1 Hirth Peter · CIK 0001813780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2031-06-17 F1 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share. Read SEC document |
| July 20, 2023 Filed Jul 21, 2023 20:13 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000213 · form4.xml · derivative · entry 1 Hirth Peter · CIK 0001813780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-07-20 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2024 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 21:53 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $53.08 | $0.00 |
DisclosureSEC source: 0001209191-23-037502 · doc4.xml · derivative · entry 3 Hirth Peter · CIK 0001813780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-06-12 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 13, 2024 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 21:53 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037502 · doc4.xml · nonDerivative · entry 1 Hirth Peter · CIK 0001813780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,625 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 13, 2024 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 08, 2023 Filed Jun 13, 2023 23:54 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 41,533 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001140361-23-029696 · form4.xml · derivative · entry 1 Hirth Peter · CIK 0001813780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,533 Underlying: Common Stock · 41,533 shares Expires 2033-06-08 F1 · derivative.exercise_date: These options vest on June 8, 2024, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 20:14 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001567619-22-013391 · doc1.xml · derivative · entry 1 Hirth Peter · CIK 0001813780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2023 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:30 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $22.70 | $0.00 |
DisclosureSEC source: 0001209191-22-034052 · doc4.xml · derivative · entry 3 Hirth Peter · CIK 0001813780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2032-05-31 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 1, 2023 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:30 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 3,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034052 · doc4.xml · nonDerivative · entry 1 Hirth Peter · CIK 0001813780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 1, 2023 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 26, 2022 Filed May 31, 2022 23:42 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 23,885 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001567619-22-011963 · doc1.xml · derivative · entry 1 Hirth Peter · CIK 0001813780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,885 Underlying: Common Stock · 23,885 shares Expires 2032-05-26 F1 · derivative.exercise_date: These options vest on May 26, 2023, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. Read SEC document |
| November 04, 2021 Filed Nov 8, 2021 23:35 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 34,731 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001140361-21-037040 · form4.xml · derivative · entry 1 Hirth Peter · CIK 0001813780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,731 Underlying: Common Stock · 34,731 shares Expires 2031-11-04 F1 · derivative.exercise_date: These options vest annually over three years from the vesting commencement date of November 4, 2021, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 21:13 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $26.58 | $0.00 |
DisclosureSEC source: 0001567619-21-012337 · doc1.xml · derivative · entry 1 Hirth Peter · CIK 0001813780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-17 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day prior to the annual meeting in 2022 of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 22:50 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $21.49 | $0.00 |
DisclosureSEC source: 0001209191-21-037901 · doc4.xml · derivative · entry 1 Hirth Peter · CIK 0001813780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-01 F1 · derivative.exercise_date: The shares subject to the option will vest monthly and fully vest on the earlier of June 2, 2022 or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.